dult stem cells' is the collective term used to describe volunteers by taking aspirates of bone marrow from the iliac postnatal stem cells which, as opposed to embryonic crest and expanding on tissue-culture plastic. [6] Over recent or fetal stem cells, persist throughout life and fulfill functions years, MSC-like cells have also been identified in a number of to repair or replace cells within certain tissues in response to different tissues. [2] Cells exhibiting MSC morphology and traumatic events or natural cell turnover. Among tissues cellular characteristics have been isolated from adult peripheral identified to harbor stem cells throughout postnatal life, bone blood, [7] adipose tissue, [8] skin tissue, [9] trabecular bone, [10] marrow has been studied for many years as a source of both well as fetal blood, liver, bone marrow [11] and lung. [12] Further hematopoietic stem cells (HSCs) and mesenchymal stem cells MSC-like populations have been discovered in umbilical cord (MSCs). Mesenchymal stem cells reside in the stromal fraction blood [13] and within the chorionic villi of the placenta. [14] of the bone marrow, which provides the cellular Amniotic fluid has also been cited as a source of MSCs, with microenvironment supporting hematopoeisis. Mesenchymal potential far-reaching implications for such areas as prenatal stem cells were first described as bone-forming progenitors diagnosis and gene therapy. [15] 'A as from the stromal fraction of rats by Friedenstein and Petrakova in 1966 [1] and Friedenstein went on to pioneer in vitro culture methods for the isolation and differentiation of MSCs. [2] MSCs have subsequently been shown to differentiate into a number of mesenchymal cell types including osteoblasts, chondrocytes and adipocytes. [3] 
Sources of Primary MSCs
MSCs are typically isolated from the stromal fraction of adult bone marrow. In fresh bone marrow, MSCs account for only 0.01-0.0001% of nucleated marrow cells. [4, 5] Murine MSCs are classically obtained from the femurs and tibias of mice by flushing the marrow out of the bones with culture medium and transferring the resultant cell suspension in culture. Human MSCs can be similarly obtained from healthy
Isolation of Primary MSCs
It is notable that, contrary to most biological systems, human MSCs are better characterized than animal MSCs. This is probably due to the fact that MSCs are easily isolated and expanded from adult human tissue collected from healthy volunteers. Mesenchymal stem cells have nevertheless been isolated from a number of other species. Along with human MSCs, the better characterized cultures are those of rat [16] and mouse [17] origin, although therapeutic potential in large animal models has been investigated with MSCs from horse, [18] cow, [19] pig, [20] dog, [21] sheep [22] and baboon. [23] Three main approaches have been described for the isolation of MSCs and can either be used independently or combined together to obtain a more homogeneous culture. The traditional isolation method relies on the fact that MSCs selectively adhere to plastic surfaces, whereas hematopoietic cells do not and can therefore be removed through medium changes. [24] Whilst this eliminates most contaminating cells, the remaining heterogeneity of the culture progressively decreases by serial passaging and after a number of passages the culture is enriched in the self-renewing fraction, the stem cells. Another published isolation protocol involves centrifugation over a Percoll gradient, which separates cell populations based on their density and allows the enrichment of nucleated cells. [4] However, both methods are quite nonspecific and an approach that is now increasingly being
Differentiation Potential
MSCs are usually grown as a monolayer culture in medium typically containing 10% fetal calf serum at 37°C in a humid environment containing 5% CO 2 . As for many other adult stem cells, MSCs are traditionally considered to only be capable of differentiating into cell types of their own original lineage, i.e., mesenchymal derivatives. We and many other groups have shown MSCs to be capable of forming osteoblasts, chrondrocytes and adipocytes both in vitro [34] and in vivo. [35] The ability of clonally expanded cells to form these three distinct cell types remains the only reliable functional criterion used, resorts to sorting of bone marrow populations by flow cytometry (FACS), based on MSC reactivity to a number of antibodies. This can either be achieved by positively selecting for expressed antigens or by a process of immunodepletion of cells expressing hematopoietic and/or other lineage antigens. For instance, antibodies against CD34, a surface marker found on hematopoietic cells, are frequently used to identify and remove nonmesenchymal cells from a marrow culture. [3] Since there is no single specific marker available to unequivocally identify the MSC, different groups have opted for a variety of marker combinations. MSCs appear relatively stable as primary cultures [25, 26] although spontaneous transformation events have been observed in long-term
Characterization of MSCs
Markers used by different groups to identify the MSC fraction from human bone marrow include, but are not limited to, CD13, CD29, CD31, CD44, CD54, CD63, CD73, CD105, CD106, CD140b, CD166 and Stro1. [3, [28] [29] [30] [31] [32] Comparisons of the various combinations used by different investigators show that the majority of subsets include either CD29, CD105 or both. We have established that over 95% of cells from the human MSC culture used in our lab express both CD29 and CD105 [ Figure 1B ]. Although these markers have been used by various groups, there is still no general consensus on the optimal marker combination for MSCs. Some of this conjecture may be due to variations in sample origin, culture techniques and media composition among laboratories or differences in the age of the donors from which the MSCs were obtained and used for available to identify the genuine MSC and distinguish it from preosteoblast, preadipocyte or prechondrocytic cells which each only give rise to one cell type. [36] Osteogenic potential Osteogenic differentiation of MSCs is induced in vitro by treating a monolayer culture with a pro-osteogenic cocktail. Standardly used differentiation medium consists of dexamethasone, ascorbic acid-2-phosphate and betaglycerophosphate. [37] Mineralized deposits can appear after a week, but the treatment is often maintained for up to three weeks in order to maximize the number and size of mineralizing nodules. Additional calcium is also used to increase in vitro mineralization. [10] Early signs of osteogenesis include an increase in bone-specific alkaline phosphatase activity, which can be measured enzymatically. [38] At the end of the treatment, cells can be fixed and stained with either Alizarin-Red S solution [10] [ Figure 1C ] or silver nitrate for von Kossa staining, [37] which highlight the calcium phosphate deposits. Quantitative measurements of mineral deposition can then be obtained by colorimetry. [10] Furthermore, osteogenic differentiation is accompanied by the expression of genes such as osterix, cbfa1, osteopontin, osteocalcin, bone sialoprotein, [39, 40] which can be monitored at the RNA and protein level. cultures. [27] immunophenotyping. Because different antibody subsets are likely to selectively isolate slightly different cell types, comparison and evaluation of published data arising from different groups can be difficult. For instance, some groups report a degree of heterogeneity in their cultures after isolation and purification, with occasional description of a subset of small rounded cells among the more common fibroblast-like phenotype [33] [ Figure 1A ]. This ambiguity begs the question of what MSCs are: do they purely represent the proliferating fibroblastic-like progenitors from the bone marrow stroma or do they include all cells capable of forming mesenchymal tissue? In the absence of a specific cell marker, MSCs may well incorporate a number of different cell populations all potentially variable in their phenotypic and growth characteristics, with mesenchymal differentiation as a common denominator. 
Chondrogenic potential
Chondrogenic differentiation is traditionally achieved by first forcing aggregation of 200,000 to 300,000 MSCs in chondrogenic medium, in order to generate a micromass pellet culture. Common to most culture protocols is the presence of dexamethasone, ascorbic acid phosphate and ITS+ supplement, which consists of bovine insulin, transferrin, selenous acid, linoleic acid and bovine serum albumin. [10] Further additives to the medium include sodium pyruvate, proline, L-glutamine and TGF-beta1, [37, 41] a growth factor involved in chondrogenesis in vivo. [42] Over the period of treatment, there is an upregulation of chondrogenic markers differentiation was supported by expression of alpha1, alpha1B, alpha1D, beta1 and beta2 adrenergic and M1 and M2 muscarinic receptors. [49] In all cases of MSCs displaying myogenic potential in vivo, [48, 50] it is not clear how much of this ability is due to de novo myogenesis and how much is due to cell fusion events with resident myoblasts.
[51] Whatever the mechanism may be, MSCs appear to provide a positive contribution to areas of muscular or cardiac damage, with no observed detrimental side-effects. [14, 52] Neural potential? Perhaps most interesting are the recent reports that under such as collagen II, collagen XI, aggrecan, perlecan and certain conditions MSCs can be made to form neural cells. syndecan. [19, 43] After two to three weeks in culture, micromass
Most studies showing the formation of both neuronal and glial pellets can then be fixed and embedded for sectioning and cells from MSCs have been carried out in vitro, subsequent staining with Safranin-O, Toluidine blue or Alcian complemented in a few instances by in vivo data, [55, 56] although highlight acid mucopolysaccharides, in many cases the possibility of cell fusion cannot be formally glycosaminoglycans and proteoglycans respectively. [10, 37, 41] ruled out. There have been a number of different approaches reported to trigger this apparent transdifferentiation in vitro.
Adipogenic potential
Some groups have used chemical treatments such as Formation of mature adipocytes occurs following treatment DMSO, [23, 57] whilst others have opted for the use of growth of MSCs with a medium supplemented with dexamethasone, factors such as fibroblast growth factor (FGF), neuronal growth isobutylmethylxanthine, insulin and a PPARgamma agonist factor (NGF) and epidermal growth factor (EGF). [53, 54, 58, 59] such as BRL 49653 [10] with twice weekly medium changes for However, recent evidence suggests that early positive results three weeks. Alternatively, MSCs can be exposed to three cycles obtained using DMSO-based protocols are unreliable, as the of a treatment which alternates three days of culture in neural-like morphology and gene expression displayed by MSCs induction medium followed by two days in maintenance after treatment were in fact due to toxicity. [60, 61] Despite this medium. [37] In this instance, the induction medium contains setback, many other groups have reported the production of indomethacin instead of BRL 49653 and the maintenance MSC-derived neurons, astrocytes, [62] oligodendrocytes [53] and medium contains insulin. The appearance of adipocytes Schwann cells [63] in vitro with varying degrees of efficiency. containing lipid-filled droplets can be demonstrated by staining There is, however, an intense ongoing debate about the nature with oil red O ( Figure 1D ) and by RT-PCR detection of adipsin, of these differentiation responses. Are they merely an artefact aP2 and PPARgamma expression. [3, 44] Quantitative data can of the in vitro process or do they represent genuine neural be obtained by enzymatic dosage of the Glycerol-3-phosphate potential from MSCs? As mentioned earlier, the multipotency dehydrogenase, a marker of the mature adipocyte. [45] of the MSC seems to be a fluid and evolving concept as novel Furthermore, an elegant technique developed by Gimble allows culture conditions and differentiation treatments are being the quantitation of adipocytes by flow cytometry in a MSC developed. culture stained with the lipophilic dye nile red. [46] Evaluating MSC Potential for Therapeutic Applications Myogenic potential In recent years, the extent of MSC multipotency has been An ideal source of adult stem cells? frequently discussed, with many authors suggesting that MSCs
The availability of autologous MSCs, which are easily accessible [53, 54] have a differentiation potential broader than initially thought. from patients, makes them a promising source of cells for many blue to
When treated with the demethylating agent 5-azacytidine, MSCs have been demonstrated to have the ability to form muscle cells. [47] Myogenic potential has also been observed in a xenogeneic in vitro model where human MSCs are co cultured with murine skeletal myocytes. [48] Furthermore, MSCs have been shown to form cardiomyocytes, [49] which is being pursued as a potential replacement for the scar tissue formed as a result of myocardial infarction. Murine MSCs were reported to start beating spontaneously two weeks after 5-azacytidine treatment as well as assuming a cardiomyocyte-like morphology. The cells displayed both sinus node-like and ventricular cell-like action potentials and the beating rate was increased by isoproterenol treatment and blocked by a beta1-selective blocker, thus exhibiting signs of physiological cardiomyogenic response. This clinical applications in the evolving field of regenerative medicine. As well as providing the scaffolding (stromal) fraction of the bone marrow for HSCs to proliferate on, MSCs are thought to play a role in hematopoiesis itself. [4] MSCs have been shown to significantly improve hematopoietic recovery in patients receiving high-dose chemotherapy when compared with autologous blood stem cell transfusion alone. [64] Koc et al [64] co-infused culture-expanded MSCs with autologous blood stem cells in breast cancer patients and observed accelerated hematopoietic recovery. human MSCs into sheep have shown that grafted cells could integrate into a variety of host tissues without any specific immune response. [66] MSCs have also been found to be immunosuppressive, through a mechanism thought to involve paracrine inhibition of T-and B-cell proliferation [67] (reviewed in [65] ) and as such have been used in trials investigating their effects on autoimmune diseases and GVHD. [68, 69] Co-infusion of donor-derived MSCs together with HSCs has been shown to reduce the incidence and severity of GVHD in sibling allografts. [70] It was recently reported that a nine-year-old patient suffering from progressive severe GVHD that was unresponsive to classical therapy was treated with a MSC intravenous been reported following transplantation in the brain. MSCs transplanted into rat striata were seen to migrate across the corpus callosum and populate the striatum, thalamic nuclei and substantia nigra of the 6-OHDA-lesioned hemisphere. [81] Untreated MSCs systemically infused into animals with damaged brain tissue have also been seen to migrate to the trauma site and improve recovery, although whether this is via secretion of neuroprotective factors or by differentiation into neural tissue remains unclear. Whilst it is not disputed that the MSCs appear to serve a positive role in recovery, there is debate as to whether the signs of differentiation observed in situ are genuine or merely a result of cell fusion with resident transplant from his mother and demonstrated a complete neural cells. More research is required to determine the reality [68] The hypo-immunogenic properties of MSCs are and precise extent of MSC contribution in brain repair models considered by some to be sufficient to allow transplantation even as such results could have implications for neurodegenerative between individuals who are not HLA-compatible. [71] diseases such as Parkinson's disease, Alzheimer's disease or traumatic events such as stroke or spinal cord injury. Although Applications for osteochondral repair the adult brain contains populations of neural stem cells [82, 83] MSCs represent one of the few adult stem cell populations these are insufficient to replace the massive number of cells already in use in the clinic. MSCs are currently used to develop needed to treat these conditions. The critical question has been new therapies for a number of skeletal conditions. The osteogenic to identify a source of neural progenitor cells for potential of MSCs has been utilized to treat cases of defective transplantation. The potential use of fetal tissue or fracture healing, both alone and in combination with scaffolds differentiated embryonic stem cells suffers limitations due to to repair large bone defects with a high degree of success. [72] tissue availability, ethical issues or safety concerns. The MSCs have also been used for cartilage repair. Autologous MSCs identification of an adult population of cells such as MSCs, were expanded ex vivo, embedded in a collagen gel and rewhich can be easily obtained from autologous or donated implanted into areas of articular cartilage defect in osteoarthritis marrow and can be cultured and manipulated ex vivo, would patients. [73] In this study, formation of hyaline cartilage-like tissue represent a significant breakthrough in the search for many was improved in the experimental group compared to control. applications in regenerative medicine. Although most applications for tissue repair involve local transplantation of MSCs to directly target the area of injury, Conclusion systemic transplantation of MSCs has been in place for a long time in hematopoietic stem cell transplants. Recently, children
Mesenchymal stem cells represent a population of cells with suffering from osteogenesis imperfecta were treated systemically the potential to contribute to future treatments for a wide range with allogenic MSCs. Transplanted MSCs were shown to migrate of acute or degenerative diseases. Significant progress has been to the bone and produce collagen, thus providing a new and made to identify the pharmacological and molecular pathways efficient route to alleviate the debilitating consequences of this driving MSC differentiation towards mesenchymal derivatives genetic condition. [74] in vitro and preliminary results indicate that MSCs could be used to generate neural derivatives. Much remains to be done Potential applications of MSCs for myocardiac repair in order to evaluate the physiological relevance of these early Current clinical trials are investigating the potential of MSCs observations and to unravel the molecular mechanisms for the treatment of myocardial infarction. [75] As previously governing their differentiation in vivo. Applications currently recovery.
discussed, a number of groups have reported MSC under investigation for MSC-based therapies include differentiation into cardiomyocytes in vitro. The current in vivo approach consists of injecting undifferentiated MSCs or whole bone marrow directly into the heart and, although the underlying mechanisms remains to be elucidated, significant improvement has been detected. [76, 77] The report by Chen et al [78] demonstrates a significant and sustained improvement in global left-ventricular ejection fraction, suggesting that MSC infusion triggers the formation of new cardiomyocytes and neoangiogenesis in the human heart. [79] It is still unclear whether MSCs act directly by in situ differentiation or fusion with resident myocytes [48] or indirectly through secretion of pro-myogenic factors promoting endogenous myocardial repair, such as VEGF and FGF. [80] Therapeutic potential beyond mesenchymal lineages The ability of MSCs to migrate to the site of injury has also musculoskeletal and cardiac repair, as well as genetic manipulation of MSCs for gene therapy strategies. Directed differentiation of autologous MSCs towards extramesenchymal lineages is an exciting and promising area of stem cell biology, with potential for the repair of tissues where resident stem cells are not accessible, such as the brain. MSCs thus represent an interesting and versatile population of adult stem cells demanding further molecular characterization and functional investigation. Future research will define the extent of their potential as an autologous and allogenic stem cell source for clinical application. 
